K. George Chandy

K. George Chandy

Auto-generated profile, based on publicly available information

K. George Chandy

Nanyang Technological University Singapore Singapore

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2017 in Current Opinion in Chemical Biology
Verified
Journal Article
Closed access
KCK George Chandy
K George Chandy
Raymond NortonRaymond Norton
Raymond Norton

11 September 2020 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
ZHZhisheng Her
Zhisheng Her
JTJoel Heng Loong Tan
Joel Heng Loong Tan
YLYee-Siang Lim
Yee-Siang Lim
STSue Yee Tan
Sue Yee Tan
XCXue Ying Chan
Xue Ying Chan
Qingfeng ChenQingfeng Chen
Qingfeng Chen
Non-alcoholic fatty liver disease (NAFLD) has been on a global rise. While animal models have rendered valuable insights to the pathogenesis of NAFLD, discrepancy with patient data still exists. Since non-alcoholic steatohepatitis (NASH) involves chronic inflammation, and CD4+ T cell infiltration of the liver is characteristic of NASH patients, we established and characterized a humanized mouse model to identify human-specific immune response(s) associated with NAFLD progression. Immunodeficient mice engrafted with human immune cells (HIL mice) were fed with high fat and high calorie (HFHC) or chow diet for 20 weeks. Liver histology and immune profile of HIL mice were analyzed and compared with patient data. HIL mice on HFHC diet developed steatosis, inflammation and fibrosis of the liver. Human CD4+ central and effector memory T cells increased within the liver and in the peripheral blood of our HIL mice, accompanied by marked up-regulation of pro-inflammatory cytokines (IL-17A and IFNγ). In vivo depletion of human CD4+ T cells in HIL mice reduced liver inflammation and fibrosis, but not steatosis. Our results highlight CD4+ memory T cell subsets as important drivers of NAFLD progression from steatosis to fibrosis and provides a humanized mouse model for pre-clinical evaluation of potential therapeutics.

29 December 2025 in British Journal of Pharmacology
Verified
Journal Article
Open access
SASteve Alexander
Steve Alexander
JSJörg Striessnig
Jörg Striessnig
AGAlasdair J. Gibb
Alasdair J. Gibb
AMAlistair A. Mathie
Alistair A. Mathie
EVEmma L. Veale
Emma L. Veale
Michael ZhuMichael Zhu
Michael Zhu
The Concise Guide to Pharmacology 2025/26 marks the seventh edition in this series of biennial publications in the British Journal of Pharmacology. Presented in landscape format, the guide provides a comparative overview of the pharmacology of drug target families. The concise nature of the Concise Guide refers to the style of presentation, being clear, accessible, and well‐structured, rather than the scope of the content, which spans approximately 500 pages. The Concise Guide summarises the key pharmacological properties of around 1900 human drug targets, and nearly 7000 interactions, involving around 4400 ligands. While the content is a substantially condensed version of the more detailed information and links available at the www.guidetopharmacology.org website, the printed guide serves as a permanent, citable, point‐in‐time record, that remains stable despite ongoing updates to the online database. The full contents of this publication can be found at https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bph.70231 . The Concise Guides provide expert‐curated recommendations of ‘Gold Standard’ selective pharmacological tools, available either commercially or as donations, which enable the identification of individual drug targets or families of drug targets. While the Concise Guide offers a more streamlined overview, more comprehensive information, including detailed pharmacological profiles and links to multiple online databases, is available through the Guide to Pharmacology website. The 2025/26 edition of the Concise Guide is based on material current as of mid‐2025, and supersedes all previous editions, including the 2023/24 Guide, and earlier Guides to Receptors and Channels. It is produced in close conjunction with the Nomenclature and Standards Committee of the International Union of Basic and Clinical Pharmacology (NC‐IUPHAR), and as such provides official IUPHAR classification and nomenclature for human drug targets, where applicable. Ion channels are one of the six major pharmacological targets into which the Guide is divided, with the others being: G protein‐coupled receptors, nuclear hormone receptors, catalytic receptors, enzymes and transporters. Each section includes nomenclature guidance, concise summaries, information of the best available pharmacological tools, key references, and suggestions for further reading.

1 December 2017 in Neuropharmacology
Verified
Journal Article
Closed access
Raymond NortonRaymond Norton
Raymond Norton
KCK. George Chandy
K. George Chandy

28 January 2022 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
ATAnu Tyagi
Anu Tyagi
TATofayel Ahmed
Tofayel Ahmed
SJShi Jian
Shi Jian
SBSaumya Bajaj
Saumya Bajaj
SOSeow Theng Ong
Seow Theng Ong
SBShashi Bhushan
Shashi Bhushan
Significance: Voltage-gated potassium channels (Kv) open with membrane depolarization and allow the flow of K + ions. Ion flow is tightly governed by time-dependent entry into nonconducting inactivated states. Here, we focus on Kv1.3, a channel of physiological importance in immune cells. We used cryogenic electron microscopy to determine structures of human Kv1.3 alone and bound to dalazatide, a peptide inhibitor in human trials. In the unbound state, Kv1.3’s outer pore is rearranged compared to all other K + channels analyzed. Interaction of dalazatide with Kv1.3’s outer pore causes a dynamic rearrangement of the selectivity filter as Kv1.3 enters a drug-blocked state.

17 February 2020 in Natural Product Reports
Verified
Journal Article
Closed access
PDF file
SBSaumya Bajaj
Saumya Bajaj
SOSeow Theng Ong
Seow Theng Ong
KCK. George Chandy
K. George Chandy
Covering: Up to 2020 Ion channels are a vast super-family of membrane proteins that play critical physiological roles in excitable and non-excitable cells. Their biomedical importance makes them valuable and attractive drug targets for neurological, cardiovascular, gastrointestinal and metabolic diseases, and for cancer therapy and immune modulation. Current therapeutics target only a minor subset of ion channels, leaving a large unexploited space within the ion channel field. Natural products harnessed from the almost unlimited and diverse universe of compounds within the bioenvironment have been used to modulate channels for decades. In this review we highlight the impact made by natural products on ion channel pharmacology, specifically on K+, NaV and CaV channels, and use case studies to describe the development of ion channel-modulating drugs from natural sources for the treatment of pain, heart disease and autoimmune diseases.